ECSP22048726A - USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS - Google Patents
USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERSInfo
- Publication number
- ECSP22048726A ECSP22048726A ECSENADI202248726A ECDI202248726A ECSP22048726A EC SP22048726 A ECSP22048726 A EC SP22048726A EC SENADI202248726 A ECSENADI202248726 A EC SENADI202248726A EC DI202248726 A ECDI202248726 A EC DI202248726A EC SP22048726 A ECSP22048726 A EC SP22048726A
- Authority
- EC
- Ecuador
- Prior art keywords
- reboxetine
- nervous system
- system disorders
- treat nervous
- esreboxetine
- Prior art date
Links
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 title abstract 4
- 229960003770 reboxetine Drugs 0.000 title abstract 4
- 208000012902 Nervous system disease Diseases 0.000 title 1
- CBQGYUDMJHNJBX-OALUTQOASA-N (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 abstract 3
- 229950008247 esreboxetine Drugs 0.000 abstract 3
- 201000003631 narcolepsy Diseases 0.000 abstract 3
- 208000023046 narcolepsy-cataplexy syndrome Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001573 Cataplexy Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento se describen los m?todos para el tratamiento de la narcolepsia con cataplexia, los cuales comprenden la administraci?n de la reboxetina (la que incluye la esreboxetina) a un ser humano que lo necesite. La reboxetina (la que incluye la esreboxetina) tambi?n se puede utilizar en la elaboraci?n de un medicamento para el tratamiento de la narcolepsia con cataplexia. Tambi?n se dan a conocer en este documento los kits que comprenden una composici?n farmac?utica que comprende la reboxetina (la que incluye la esreboxetina) y las instrucciones para usar la composici?n farmac?utica para el tratamiento de la narcolepsia con cataplexia en un ser humano.Described herein are methods for treating narcolepsy with cataplexy, including administering reboxetine (including esreboxetine) to a human in need. Reboxetine (which includes esreboxetine) can also be used in the manufacture of a drug for the treatment of narcolepsy with cataplexy. Kits comprising a pharmaceutical composition comprising reboxetine (which includes esreboxetine) and instructions for using the pharmaceutical composition for the treatment of narcolepsy are also disclosed herein. with cataplexy in a human.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943077P | 2019-12-03 | 2019-12-03 | |
| US201962946295P | 2019-12-10 | 2019-12-10 | |
| US16/740,329 US20200147093A1 (en) | 2018-10-15 | 2020-01-10 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US16/740,409 US11351175B2 (en) | 2018-10-15 | 2020-01-11 | Use of reboxetine to treat narcolepsy |
| US16/740,410 US20200147095A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US16/740,411 US20200147096A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22048726A true ECSP22048726A (en) | 2022-07-29 |
Family
ID=76221823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202248726A ECSP22048726A (en) | 2019-12-03 | 2022-06-17 | USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS |
Country Status (4)
| Country | Link |
|---|---|
| CL (1) | CL2022001476A1 (en) |
| EC (1) | ECSP22048726A (en) |
| TW (2) | TW202313055A (en) |
| WO (1) | WO2021113163A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60022692T2 (en) * | 1999-07-01 | 2006-06-22 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S, S) reboxetine for the treatment of migraine headache |
| JP2008501778A (en) * | 2004-06-09 | 2008-01-24 | ファイザー・インク | Use of reboxetine for the treatment of pain |
| US9359290B2 (en) * | 2013-03-13 | 2016-06-07 | Jazz Pharmaceuticals International Iii Limited | Treatment of cataplexy |
| CN112888430A (en) * | 2018-10-15 | 2021-06-01 | 艾克萨姆治疗公司 | Use of reboxetine for the treatment of narcolepsy |
-
2020
- 2020-11-30 WO PCT/US2020/062560 patent/WO2021113163A1/en not_active Ceased
- 2020-12-02 TW TW111147054A patent/TW202313055A/en unknown
- 2020-12-02 TW TW109142504A patent/TWI790510B/en active
-
2022
- 2022-06-03 CL CL2022001476A patent/CL2022001476A1/en unknown
- 2022-06-17 EC ECSENADI202248726A patent/ECSP22048726A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI790510B (en) | 2023-01-21 |
| TW202313055A (en) | 2023-04-01 |
| TW202128179A (en) | 2021-08-01 |
| WO2021113163A1 (en) | 2021-06-10 |
| CL2022001476A1 (en) | 2023-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000924A1 (en) | Use of reboxetine for the treatment of narcolepsy | |
| MX2023000735A (en) | METHODS AND COMBINATIONS OF KAT6 INHIBITOR FOR THE TREATMENT OF CANCER. | |
| CL2022001743A1 (en) | Gamma-Hydroxybutyrate (GHB) Dosage | |
| GT201700246A (en) | METHODS AND KITS TO TREAT DEPRESSION | |
| MX2022010357A (en) | ANTI-PCSK9 INHIBITORY ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH HYPERLIPIDEMIA WHO UNDERGO LIPOPROTEIN PHHERESIS. | |
| MX380767B (en) | METHODS TO REDUCE CARDIOVASCULAR RISK. | |
| MX2019003134A (en) | Combination therapy. | |
| CO2017012381A2 (en) | Mono or disubstituted indole derivatives as inhibitors of dengue viral replication | |
| MX2020001768A (en) | METHODS OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMIC CANABIDIOL GEL. | |
| BR112017006113A8 (en) | Auristatin uses, pharmaceutical compositions, dosage forms for cancer treatment and kits. | |
| MX2022014792A (en) | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF AND TREATMENT METHODS INVOLVING THEM. | |
| CL2020000270A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor. | |
| MX2018016332A (en) | COMBINATION CHEMOTHERAPIES. | |
| BR112023005160A2 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | |
| CO2022014499A2 (en) | nlrp3 modulators | |
| CL2021001976A1 (en) | Treatment of skin lesions and pruritus in patients with nodular prurigo | |
| MX2024003918A (en) | THERAPEUTIC AGENT THAT INDUCES CYTOTOXICITY FOR USE IN CANCER THERAPY. | |
| MX2021008941A (en) | Gpr35 modulators. | |
| BR112022010702A2 (en) | MACROCYCLES FOR USE IN THE TREATMENT OF DISEASES | |
| CL2021001830A1 (en) | lta4h inhibitors for the treatment of hidradenitis suppurativa | |
| MX2021011263A (en) | Use of gabaa receptor modulators for treatment of pain. | |
| ECSP22048726A (en) | USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS | |
| MX2023015070A (en) | Anti-cd40 antibody, antigen-binding fragment and medical use thereof. | |
| BR112019004540A2 (en) | method for treating dementia in a patient, pharmaceutical composition, method for treating dementia in a patient, method for reducing the likelihood of developing dementia in a patient, composition for use in treating dementia in a patient, composition and composition for use in reducing dementia likelihood of developing dementia in a patient undergoing long therapy with a non-steroidal anti-inflammatory drug or aspirin | |
| PE20230181A1 (en) | USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS |